|
|
 Previous Article | Table of Contents | Next Article 
Use of  -2a-Interferon to Treat Cytogenetic Relapse of Chronic Myeloid Leukemia After Marrow Transplantation
Celestia S. Higano,
Deborah Chielens,
Wendy Raskind,
Eileen Bryant,
Mary E.D. Flowers,
Jerald Radich,
Reginald Clift, and
Frederick Appelbaum
From the Divisions of Oncology and General Internal Medicine, University of Washington and Fred Hutchinson Cancer Research Center, Seattle.
Fourteen patients with cytogenetic relapse of chronic myeloid leukemia (CML) after transplantation with unmanipulated bone marrow were treated with  -2a-interferon. There were eight men and six women, median age, 33 years. Twelve patients received marrow from a related allogeneic donor and two received marrow from a syngeneic donor. The median percentage of Ph-positive metaphases at the time of starting interferon was 55% (10% to 87%). Daily interferon was started at a dose of 1 to 3 × 106 U/M2/d, depending on initial blood counts and was adjusted as tolerated to maintain the white blood count in the range of 2,000 to 3,000/µL and the platelet count greater than 60,000/µL. After a stable cytogenetic remission was achieved, the interferon dose was decreased to a maintenance level. Twelve patients achieved a complete cytogenetic remission on at least one occasion. Median time to achieve a complete cytogenetic remission was 7.5 months (range, 1.5 to 12). Eight patients remain in cytogenetic remission for 10+ to 54+ months from the time of first documented remission. After complete cytogenetic remission was established, nine patients were tested for the presence of the mRNA transcript of the bcr/abl fusion gene by polymerase chain reaction (PCR) testing. Four patients were PCR-negative on at least one occasion: two patients were PCR-negative on a single occasion; one patient had serial tests, which were PCR-negative; and one patient had serial PCR-negative peripheral blood tests with a single PCR-positive bone marrow obtained concurrently with a negative peripheral blood test. Median follow-up time for all patients is 44 months (range, 20 to 64). Interferon was generally well tolerated; only one responding patient was unable to continue interferon because of toxicity. Interferon induces durable cytogenetic remissions in a significant proportion (57%) of patients with cytogenetic relapse following bone marrow transplantation (BMT) without causing life-threatening toxicities.
Blood, Vol. 90 No. 7 (October 1), 1997:
pp. 2549-2554
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Berger, M. E. Flowers, E. H. Warren, and S. R. Riddell
Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation
Blood,
March 15, 2006;
107(6):
2294 - 2302.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Kantarjian, S. O'Brien, J. E. Cortes, S. A. Giralt, M. B. Rios, J. Shan, F. J. Giles, D. A. Thomas, S. Faderl, M. De Lima, et al.
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia
Blood,
August 13, 2002;
100(5):
1590 - 1595.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Druker, S. G. O'Brien, J. Cortes, and J. Radich
Chronic Myelogenous Leukemia
Hematology,
January 1, 2002;
2002(1):
111 - 135.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
E. Olavarria, E. Kanfer, R. Szydlo, J. Kaeda, K. Rezvani, K. Cwynarski, C. Pocock, F. Dazzi, C. Craddock, J. F. Apperley, et al.
Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia
Blood,
March 15, 2001;
97(6):
1560 - 1565.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Dazzi, R. M. Szydlo, N. C. P. Cross, C. Craddock, J. Kaeda, E. Kanfer, K. Cwynarski, E. Olavarria, A. Yong, J. F. Apperley, et al.
Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia
Blood,
October 15, 2000;
96(8):
2712 - 2716.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Craddock, R. M. Szydlo, J. P. Klein, F. Dazzi, E. Olavarria, F. van Rhee, C. Pocock, K. Cwynarski, J. F. Apperley, and J. M. Goldman
Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission
Blood,
July 1, 2000;
96(1):
86 - 90.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Serrano, J. Roman, J. Sanchez, A. Jimenez, J. A. Castillejo, C. Herrera, M. G. Gonzalez, L. Reina, M. d. C. Rodriguez, M. A. Alvarez, et al.
Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210BCR-ABL and p190BCR-ABL after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190BCR-ABL detection precede cytogenetic relapse
Blood,
April 15, 2000;
95(8):
2659 - 2665.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. L. Sawyers
Chronic Myeloid Leukemia
N. Engl. J. Med.,
April 29, 1999;
340(17):
1330 - 1340.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Luis Steegmann, F. Casado, E. Granados, J. Maria Fernandez Ranada;, and C. S. Higano
Treatment of Chronic Myeloid Leukemia Relapsing After Allogeneic Bone Marrow Transplantation: The Case for Giving Interferon
Blood,
April 1, 1998;
91(7):
2617 - 2619.
[Full Text]
[PDF]
|
|
|
|
|
